Vitamin C lowered blood pressure and long-term blood sugar in diabetes trials

Vitamin C is cheap, widely available and has been floated for years as a possible add-on therapy in type 2 diabetes, partly on the logic that oxidative stress plays a role in the condition. Small trials have hinted at benefits, but hints from small trials are exactly how supplement myths get started. What matters is whether the pooled evidence shows an effect on the numbers that drive diabetes outcomes, meaning long-term blood sugar, cholesterol, triglycerides and blood pressure, and how much confidence that evidence deserves. This review set out to answer both questions at once.

The authors searched four databases and clinical trial registries for randomised controlled trials of oral vitamin C in adults with type 2 diabetes, up to September 2020. Trials were excluded if the supplement was not exclusively vitamin C or if they ran for under 2 weeks. Twenty-eight studies with 1,574 participants qualified. The primary outcomes were HbA1c, glucose, cholesterol, triglycerides and blood pressure, comparing changes between vitamin C and control groups. Crucially, the team also graded the certainty of the evidence for each outcome rather than treating every finding as equal.

Three outcomes moved to a statistically and clinically significant degree. Systolic blood pressure fell by 6.27 mmHg, and this was the most trustworthy result, backed by moderate certainty evidence. HbA1c fell by 0.54% and diastolic blood pressure by 3.77 mmHg, but both of those findings rest on very low certainty evidence. The other primary outcomes did not shift to a significant extent. The limitations were consistent across the field: studies were predominantly shorter than six months and typically enrolled fewer than 100 people, which is why the authors conclude vitamin C cannot currently be recommended as a therapy.

This is the pattern that often emerges when a cheap, plausible supplement gets a rigorous audit: real signals in the data, wrapped in evidence too weak to act on. The blood pressure finding is the most interesting, since it carried moderate certainty and a size that would be clinically relevant if it held up in bigger trials. The review neither vindicates vitamin C as a diabetes therapy nor buries it; instead it defines precisely what larger, longer and higher-quality trials now need to confirm. Until those trials exist, the question stays open.

If you manage type 2 diabetes, this is worth knowing as a live research lead rather than a reason to add anything to your routine. The authors themselves state that vitamin C cannot currently be recommended as a therapy, and the most eye-catching numbers here rest partly on very low certainty evidence. It is also a useful reminder that a statistically significant result and a recommendation-ready result are two different things. File this one under promising, unproven, and being watched.